Scilex Holding

Chronic Lower Back Pain Pipeline Shows Mixed Results as Multiple Phase III Trials Report Outcomes

- Spine BioPharma's SB-01 (vicatertide) failed to meet Phase III endpoints in 417 patients with degenerative disc disease, attributed to unexpectedly strong placebo effects at certain trial sites. - Persica Pharmaceuticals' PP353, a novel non-opioid intradiscal injection, achieved its primary endpoint in a Phase Ib trial, showing statistically significant pain reduction in 44 patients with chronic low back pain. - The chronic lower back pain pipeline includes over 10 companies developing more than 10 treatment therapies, with emerging candidates spanning from Phase I to Phase III development stages. - Recent regulatory activity includes FDA approval of Tonmya for fibromyalgia and IND authorization for Contineum's PIPE-791 targeting chronic pain conditions including low back pain.